Can the Cardiovascular Risk Reductions Observed with Empagliflozin in the EMPA-REG OUTCOME Trial be Explained by Concomitant Changes Seen in Conventional Cardiovascular Risk Factor Levels?

Citation
Coleman RL, Grab AM, Broedl UC, et al. Diabetes Obes Metab 2020; epub ahead of press.